CD274 and neoplasm: Tumor response occurred with similar frequency in patients with PD‐L1 CPS ≥ 20 versus CPS 0–19 disease (40%: 8 of 20 vs. 52%: 13 of 25), in patients with versus without tumor response to prior PD‐1 inhibitor (50%: 6 of 12 vs. 45.5%: 15 of 33), and in patients who enrolled ≤ 3 months versus > 3 months since completion of prior PD‐1 inhibitor (47.4%: 18 of 38 vs. 37.5%: 3 of 8).